Ablatus Therapeutics is a UK-based medical device company focused on developing targeted thermal ablation technologies for the treatment of various tumors. Their devices aim to improve patient outcomes by precisely destroying cancerous tissue while minimizing damage to surrounding healthy structures.
Funding
$118K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Thermal ablation, a common method for tumor treatment, often lacks precision, leading to potential damage to surrounding healthy tissue and incomplete tumor removal. This can result in complications, recurrence, and the need for additional treatments.
Solution
Ablatus Therapeutics develops targeted thermal ablation technologies designed to precisely destroy tumors while minimizing damage to adjacent healthy tissue. Their devices utilize advanced imaging and delivery systems to ensure accurate targeting and controlled energy deposition. By focusing the thermal energy specifically on the tumor, Ablatus aims to improve patient outcomes by reducing complications and increasing the likelihood of complete tumor eradication. The technology offers a less invasive alternative to traditional surgery, potentially leading to faster recovery times and improved quality of life for patients.
Target Audience
The primary target audience includes oncologists, surgeons, and interventional radiologists specializing in tumor treatment, as well as hospitals and cancer centers seeking advanced ablation technologies.
Features
- Targeted energy delivery systems for precise tumor ablation
- Real-time imaging integration for accurate targeting and monitoring
- Minimally invasive procedures, reducing patient trauma and recovery time
- Customizable treatment parameters to adapt to different tumor types and sizes
- Integrated safety mechanisms to prevent damage to surrounding healthy tissue